Medicine recalls
|
| |
| The United States: Gilead issues voluntary nationwide recall of one lot of Veklury (Remdesivir) for Injection 100 mg/vial due to the presence of a glass particle |
| |
The United States Food and Drug Administration (FDA) announces that Gilead Sciences, Inc. (Gilead) issued a voluntary nationwide recall of one lot of Veklury (Remdesivir) for Injection 100 mg/vial (Lot number: 47035CFA) to the consumer level due to the presence of a glass particle. Gilead received a customer complaint and confirmed the presence of a glass particle in the vial during the company's investigation.
The administration of an injectable product that contains glass particles may result in local irritation or swelling in response to the foreign material. The glass particulate can potentially travel, through the blood vessels, to various organs and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death. To date, Gilead has not received any reports of adverse events related to this recall.
Please refer to the following website in FDA for details:
http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due
In Hong Kong, Veklury Powder For Concentrate For Solution For Infusion 100mg (HK-66766) is a pharmaceutical product registered by Gilead Sciences Hong Kong Limited (Gilead). The product is a prescription-only medicine. As confirmed with Gilead, the affected lot has not been imported into Hong Kong.
Ends/Tuesday, Sep 24, 2024
Issued at HKT 15:00
|
| |
